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Background: Poor quality of life (QoL) is a feature of people with Parkinson's disease (PD) who develop
dementia. The relationship between mild cognitive impairment in PD (PD-MCI) and QoL is less clear. To
address this, we studied the impact of varying severities of cognitive impairment on QoL in a cohort of
non-demented patients with early PD.
Method: Patients with newly diagnosed PD (n ¼ 219) and age and sex matched healthy controls (n ¼ 99)
completed a schedule of neuropsychological tests, in addition to scales assessing QoL (PDQ-39),
depression, sleep, neuropsychiatric symptoms and a clinical examination. The Movement Disorder So-
ciety criteria were used to deﬁne and classify PD-MCI.
Results: Participants with PD-MCI were signiﬁcantly older than those with normal cognition, had more
severe motor symptoms, scored higher for depression and had poorer quality of life. Logistic regression
showed that mild cognitive impairment, independent of other factors, was an indicator of poorer QoL.
Using cognitive performance 2.0 standard deviations (SD) below normative data as a cut-off to deﬁne
PD-MCI, there was a signiﬁcant difference in QoL scores between patients with PD-MCI and those
classiﬁed as having normal cognition. Subjects with less severe mild cognitive impairment did not
exhibit signiﬁcant differences in QoL.
Conclusions: PD-MCI is a signiﬁcant, independent factor contributing to poorer QoL in patients with
newly diagnosed PD. Those classiﬁed with greatest impairment (2.0 SD below normal values) have lower
QoL. This has implications for clinical practice and future interventions targeting cognitive impairments.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Poor quality of life (QoL) and impaired wellbeing are common in
Parkinson's disease dementia (PDD) [1], a frequent complication of
Parkinson's disease (PD). The point prevalence of PDD is 25e30%,
which is six times higher than an aged-matched general population
[2]. Cumulatively the prevalence of PDD is estimated to be up to
80% [3]. PDD is associated with increased risk of falls, caregiver
burden, nursing home placement and increased mortality [1e3]. In
addition, fractures, urinary incontinence, hallucinations and
neuropsychiatric symptoms are also common in PDD and impact
on QoL.nit, Institute for Ageing and
itality, Newcastle Upon Tyne
son).
r Ltd. This is an open access articleThe Movement Disorder Society (MDS) Task Force deﬁnes mild
cognitive impairment in PD (PD-MCI) as performing 1 to 2 standard
deviations (SD) below appropriate normative values in neuropsy-
chological tests with no impairments of activities of daily living
(ADL) [4]. It is a potential early marker for the development of PDD
[5e7] so may also be associated with poorer QoL [8]. The preva-
lence of PD-MCI is between 15 and 40% at the time of PD diagnosis
[1,6,7]. This variability may be due to a lack of consensus in deﬁning
PD-MCI, which did not exist until the proposed diagnostic MDS
criteria were agreed upon in 2011. A recent review of the literature
showed a wide variation in the tests used to diagnose PD-MCI and
inconsistencies in the criteria used [9]. The lack of consistent cut-
offs leaves much room for variation across studies. A cut-off of
below 1.5 SD of normative data of age-matched controls was the
most common criterion used.
The relationship between PD-MCI and QoL is unclear; currently
only two studies have used the MDS Task Force diagnostic criteriaunder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
R.A. Lawson et al. / Parkinsonism and Related Disorders 20 (2014) 1071e10751072to investigate QoL in PD-MCI [1,8]. It is vital to understand the
contribution MCI and cognitive decline has on PD patients, in
addition to the motor and non-motor symptoms, and the extent to
which it inﬂuences QoL. Understanding the impact of PD-MCI
would help guide clinicians as to what pharmacological and non-
pharmacological interventions might be particularly effective
[10e12]. We therefore investigated whether the degree of severity
of PD-MCI independently inﬂuences QoL in patients with newly
diagnosed PD. This is also the ﬁrst study to examine the effects of
PD-MCI on QoL in a large cohort of early PD and to explore the
impact that different operational cut-offs for diagnosing PD-MCI
have on QoL. We hypothesized that those with PD-MCI would
have a poorer QoL compared to those with normal cognition.
2. Methods
2.1. Participants
This study was approved by the Newcastle and North Tyneside Research Ethics
Committee and performed according to the Declaration of Helsinki. All participants
provided written informed consent.
Participants were recruited from community and outpatient clinics through
general practitioners, neurologists, geriatricians and PD nurse specialists in New-
castle upon Tyne, Gateshead and Cambridgeshire as part of the Incidence of
Cognitive Impairments in Cohorts with Longitudinal Evaluation-Parkinson's Disease
(ICICLE-PD) study. All patients were newly diagnosed with idiopathic PD by a
movement disorder specialist and fulﬁlled Queen's Square Brain Bank criteria [13].
All participants underwent detailed clinical assessment, including carer interviews,
to exclude dementia. Participants were excluded if they had signiﬁcant cognitive
impairment at presentation (Mini Mental State Examination (MMSE) < 24) that
impaired ADL, met DSM-IV criteria for dementia or a diagnosis of dementia [2]. Age-
sex matched healthy controls were recruited through word of mouth and local
advertising to provide normative data.
2.2. Scales and assessments
Participants and controls completed a schedule of neuropsychological tests.
Global cognitive functionwas assessed using the MMSE [14] and Montreal Cognitive
Assessment (MoCA) [15]. Table 1 shows the neuropsychological assessments used.
Selective tests from the computerized Cognitive Drug Research (CDR) battery [16]
and Cambridge Neuropsychological Test Automated Battery (CANTAB) [17] were
used to assess attention, memory and executive function. The phonemic ﬂuency test
asked participants to generate as many words as they could in 60 s beginning with
the letter F [18]. Similarly, the semantic ﬂuency test asked participants to list as
many animals as they could in 90 s [18]. Visuospatial function was evaluated using
the pentagon copying item within the MMSE [14] and was graded using a modiﬁed
0e2 rating scale [19].
Consistent with the MDS Task Force criteria [4], participants were classiﬁed as
having PD-MCI if they scored 1 to 2 SD below the means of appropriate norms
(controls) on at least two neuropsychological tests across ﬁve cognitive domains:
attention, executive function, visuospatial function, memory and language. For data
that was not normally distributed and could not be transformed appropriately,
percentiles derived from a normal distribution were used to estimate cut-offs 1 SD
(16th percentile),1.5 SD (7th percentile) and 2 SD (2nd percentile), therefore the cut-
offs give approximately the correct percentage of people impaired. For example, theTable 1
Neuropsychological tests.
Domain Test
Attention CDR:
Power of attention
Digit vigilance
Executive function CANTAB: One touch tower of London (OTS)
Phonemic ﬂuency
Semantic ﬂuency
Visuospatial function Pentagons
Memory CANTAB:
Pattern recognition memory (PRM)
Spatial recognition memory (SRM)
Paired associate learning (PAL)
Language MoCA:
Naming
Language
CDR ¼ Cognitive Drug Research Battery, CANTAB ¼ Cambridge Neuropsychological
Test Automated Battery, MoCA ¼ Montreal Cognitive Assessment.pentagon scorewas assessed as 2 (shape includes 10 angles and clear intersection), 1
(two intersecting ﬁgures, one with ﬁve angles) or 0 (less acceptable copy); using
corresponding percentiles from the control group, participants scoring 1 were
classiﬁed as having impairment at the 1 SD and 1.5 SD level, and participants scoring
0 were classiﬁed as having impairment at the 2 SD level.
Implementation of our schedule of neuropsychological tests preceded the
establishment of MDS criteria. However, broadly we were able to meet Level II
criteria with our testing, despite having only one test speciﬁc for visuospatial
impairment.We investigated the differences using 1 SD,1.5 SD and 2 SD. These three
cut-offs have been used in other studies, although 1.5 SD is the most common [8].
Additionally, subjective cognitive decline and functional independence of partici-
pants were determined through semi-structured interviews with participants and/
or their carers.
Quality of life was measured using the Parkinson's Disease Questionnaire (PDQ-
39) [20], which is widely used in PD research and clinics [6]. It includes a 39 item
Likert scale covering eight domains: mobility, ADL, emotional wellbeing, stigma,
social support, cognition, communication and bodily discomfort. The single index of
this scale was used as a global measure of QoL in PD. The single index scores range
from 0, (best possible QoL), to 100 (worst possible QoL).
Demographic information, including age, sex and education was collected.
Participants also completed theMDS Uniﬁed Parkinson's Disease Rating Scale (MDS-
UPDRS) Part III [21]. Premorbid intelligence was measured using the National Adult
Reading Test (NART) [22]. Depression was assessed using the Geriatric Depression
Score (GDS-15) [23]; a cut-off of5 suggested possible depression. Neuropsychiatric
symptoms were measured by the Neuropsychiatric Inventory (NPI-D) [24]. Partici-
pants were assessed when “on.” Levodopa equivalent dose was calculated for all
dopaminergic medications [25].
2.3. Statistical analysis
Statistical analyses were performed using SPSS software (Version 19.0; SPSS,
Inc., Chicago, IL). Data were examined for normality of distribution with visual
histograms and KolmogoroveSmirnov's test. Comparisons of means between two
groups were performed using independent t-tests or ManneWhitney U test as
appropriate. For more than two group comparison one way ANOVAs or Krus-
kaleWallis tests were used as appropriate. Multiple comparisons were corrected
using Bonferroni's correction; the cut-off for signiﬁcance was calculated using a/n
where a is the signiﬁcance level (0.05) and n is the number of tests. Logistic
regression was used to build a model to predict QoL; data were dichotomized using
the median, such that scores below the median were low and scores above the
median were high.3. Results
Participants (n ¼ 219) were aged between 35 and 87 years
(mean of 65.9, SD ¼ 9.7); 63.9% were male (n ¼ 140). Mean time
since diagnosis was 5.5 months (SD ¼ 5.0), 83% were rated as
Hoehn and Yahr stage 1 or 2 and 16% were drug naïve. The ages of
the control subjects (n ¼ 99) ranged from 48 to 88 years (mean of
67.9, SD¼ 8.2) and 55%weremale (n¼ 54). Therewas no signiﬁcant
difference between age (p ¼ 0.06) and sex (p ¼ 0.11) of PD partic-
ipants and controls. Neither was there a signiﬁcant difference be-
tween PD participants and controls in terms of number of years of
education (mean of 13.1 SD ¼ 3.4 and 12.8 SD ¼ 3.6, respectively;
p ¼ 0.36) and NART scores (mean of 115.8, SD ¼ 8.7 and 114.3,
SD ¼ 10.3, respectively; p ¼ 0.37).
The clinical characteristics of the cohort according to different
levels of PD-MCI are shown in Table 2. PD participants classiﬁed as
normal cognition (PD-CN) scored within 1 SD of normative data.
Three MCI groups were deﬁned: MCI 1 SD which included those
with a score of 1 SD but <1.5 SD below normative data (23.2%);
MCI 1.5 SD which included those with a score 1.5 SD but < 2 SD
below normative data (21.1%); and MCI 2 SD who scored 2 SD
below normative data (22.4%). In each group, participants scored
below the means of appropriate norms (controls) on at least two
neuropsychological tests for that standard deviation.
As a group, participants with PD-MCI (1 SD below normative
data) were most commonly impaired in executive function (67%),
memory (61%) and attention (51%) domains. They were signiﬁ-
cantly older, had spent fewer years in education and had a lower
premorbid IQ (NART) (p < 0.01) than PD-CN. They also had a higher
MDS-UPDRS III score (p < 0.01) and Hoehn and Yahr stage
Table 2
Mean and standard deviation of clinical data across four groups.
Normal cognition (n ¼ 75) MCI 1SD (n ¼ 51) 1.5 SD MCI (n ¼ 44) 2 SD MCI (n ¼ 49) F/c2
M SD M SD M SD M SD
Age (years) 61.2 10.0 67.3 8.4 68.9 8.8 69.0 8.7 10.6**
Education (years) 14.4 3.7 13.1 3.3 11.2 2.4 11.4 3.7 42.6** a,b
NART 118.4 7.2 115.2 10.5 112.1 10.2 108.9 11.6 26.5** b
PD Duration (months) 5.3 4.9 6.1 4.8 5.8 6.9 4.8 3.3 2.7
Time since symptom onset (months) 18.7 13.5 26.1 20.6 28.7 37.6 26.7 25.1 6.7
UPDRS III Total 23.0 9.4 27.2 10.4 31.7 11.9 31.6 13.9 8.6**
Hoehn and Yahra 2.0 1.0 2.0 0.0 2.0 0.0 2.0 1.0 19.1**
Levodopa equivalent dose (mg/d)a 100.0 220.0 120.0 224.0 130.0 200.0 150.0 200.0 3.2
MoCA 27.4 1.8 26.1 2.4 24.5 3.2 22.3 3.9 55.5** a,b,c
MMSE 29.3 0.9 28.8 0.9 28.5 1.3 27.9 1.6 31.7** b
Phonemic ﬂuency 14.3 4.4 11.8 4.4 9.7 4.0 9.8 4.5 15.0**
Semantic ﬂuency 25.0 5.8 21.5 5.3 19.1 5.6 16.7 6.8 21.6** b
GDS-15 2.3 1.9 2.8 2.9 2.9 2.6 4.0 4.0 10.4* b
NPI Total 6.2 3.9 7.3 4.3 5.6 5.7 7.5 5.4 1.1
NPI Distress 2.9 9.1 3.5 9.7 3.4 10.1 3.3 10.4 1.0
PDQ-39 24.3 19.4 26.6 21.9 28.8 21.1 38.2 25.2 11.7** b
*p < 0.05, **p < 0.01.
Post hoc Bonferroni correction for 3 group comparison at p < 0.017, a PD-MCI 1SD vs. PD-MCI 1.5SD; b PD-MCI 1SD vs. PD-MCI 2SD; c PD-MCI 1.5SD vs. PD-MCI 2SD.
NART ¼ National Adult Reading Test, UPDRS III ¼ Movement Disorders Society-Uniﬁed Parkinson's Disease Rating Scale Part III, MoCA ¼ Montreal Cognitive Assessment,
MMSE ¼ Mini Mental State Examination, GDS-15 ¼ Geriatric Depression Score, NPI ¼ Neuropsychiatric Inventory, PDQ-39 ¼ Parkinson's Disease Questionnaire.
a Figures are median and interquartile range.
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equivalent dose. Mean depression scores were signiﬁcantly higher
for PD-MCI group compared to PD-CN, although this is below the
suggested cut-off for possible depression (GDS-15 > 5) [23]. Post
hoc comparisons between MCI groups (Table 2) showed an overlap
in scores for PDQ-39, seen clearly in Fig.1, highlighting the variation
of QoL scores by severity of cognitive impairment. Only the 2 SD
group signiﬁcantly differed from the other groups, hence only more
marked cognitive impairment at 2 SDs had a greater impact on QoL.
Because of this, we focussed our subsequent analyses using 2 SD as
a cut-off for PD-MCI.
3.1. Predicting quality of life
Stepwise logistic regressionwas used to determine predictors of
QoL and to remove potential confounders. The ﬁnal model (Table 3)
correctly predicted 72.0% of QoL scores compared to observedFig. 1. Distribution of quality of life between cognitive groups. Graph of probability
density function of PDQ-39 scores for the discreet groups of normal cognition, PD-MCI
1 SD, PD-MCI 1.5 SD and PD-MCI 2 SD.values. Goodness of ﬁt tests yielded a Nagelkerke R Square of 0.346.
The model shows that higher scores of motor severity, depression
and neuropsychiatric symptoms predicted worse QoL (Table 3). The
presence of MCI was an independent predictor of poorer QoL.
Younger participants were predicted to have lower QoL.4. Discussion
We have shown that MCI at 2 SDs below normative values is an
independent, signiﬁcant predictor of QoL in patients with newly
diagnosed PD. QoL declines with increasing cognitive impairment
in patients with PD, evenwhen other contributory factors are taken
into account. The greatest decline is seen in those who score more
than 2 SD below normal on cognitive measures. This cut-off iden-
tiﬁes 22% of our cohort as having MCI, which is consistent with
other estimates of prevalence [9].
We have shown that increasing cognitive impairment is asso-
ciated with a number of factors, including depression and PD
severity. Therefore the operational deﬁnition of MCI used has an
inﬂuence on the association between MCI and QoL. Thus while QoL
scores were statistically different in patients with “milder” PD-MCI,
i.e. at 1 SD or 1.5 SD, the effect of cognitive impairment on QoL was
strongest if MCI was deﬁned by cognitive performance 2 SD or
more below the control mean. Therefore, there is a transition effect
at a 2 SD threshold at which cognitive difﬁculties have a noticeable
impact on people's lives. From this perspective we would suggest
that 2 SD may be an appropriate operational cut-off for deﬁning
MCI in PD.Table 3
Logistic regression model predicting quality of life.
Variable b S.E. p value Exp(b)
Age 1.05 0.39 0.007 2.86
UPDRS III 0.81 0.38 0.033 0.45
GDS-15 2.45 0.79 0.002 0.09
MCI 1.45 0.48 0.003 0.23
NPI Total 0.95 0.39 0.016 0.39
Constant 3.78 0.91 0.000 43.66
UPDRS III ¼ Movement Disorders Society-Uniﬁed Parkinson's Disease Rating Scale
Part III, GDS-15 ¼ Geriatric Depression Score, MCI ¼ Mild Cognitive Impairment
using 2 stand deviation cut-off, NPI-D ¼ Neuropsychiatric Inventory.
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which is one of only two recent studies investigating QoL in PD-MCI
using the newly outlined PD-MCI criteria by from MDS Task Force
[1,8]. Leroi et al. assessed QoL and caregiver burden in participants
classiﬁed as PD-CN, PD-MCI and PDD. As cognitive impairment
increased, QoL became more impaired across the three groups,
although only PDDwas signiﬁcantly higher [1]. This could be due to
the use of Level I criteria of “possible” PD-MCI, which offers less
diagnostic certainty than Level II criteria [4]. Our study showed
declining QoL with increasing cognitive impairment, with more
severe PD-MCI having the greatest decline in QoL. This transition
effect could indicate that these participants are likely to develop
PDD [5].
Applying the MDS Task Force Level II criteria, Reginold, et al.
found changes from premorbid cognition and PD-MCI were asso-
ciated with reduced QoL in the PDQ-39 sub-scores of stigma,
communication and social support, but not in overall QoL (PDQ-39
single index score) [8]. However, cognitive decline was estimated
using the Wechsler Test of Adult Reading (WTAR), which may over
estimate premorbid intelligence and cognitive decline [22]. Our
study, however, found signiﬁcant differences in the single index
PDQ-39 score, and was independently predicted by the presence of
PD-MCI.
Attention, memory and executive function, the ability to plan
and prioritize, were the domains most commonly affected.
Impairment in these domains has previously been directly associ-
ated with poorer QoL [26,27]; inhibiting everyday function and
impacting on ADL [12,26,28], or resulting in less effective coping
strategies [11,27]. Attentional deﬁcits can impact on instrumental
and functional ADL including bathing, eating and leisure activities,
such as reading or watching television [12]. Trigg et al. [28] have
suggested that awareness of impairment may impact on QoL.
Speculatively participants with PD-MCI may have perceived poorer
QoL in that they are aware of cognitive changes and the impact they
are having on their ADLs, and may draw comparisons to how they
are performing now in comparison to their premorbid levels of
function [28].
Interestingly, our model showed that younger PD participants
were predicted to have poorer QoL. This could reﬂect that younger
participants with PD have higher expectations of QoL than older PD
participants or ﬁnd it harder to adjust, and therefore have
perceived poorer QoL [27]. Indeed previous studies have found that
older patients with PD are more accepting of disability and
impairment as they are perceived as being appropriate to their age
[29]. Younger participants may also perceive having PD as “unfair”
and are less able to deal with stigma and experience more severe
psychosocial consequences [29].
The main strengths of this study are the large cohort of newly
diagnosed PD patients and the range of validated instruments
used to assess motor and non-motor symptoms, including a
detailed schedule of neuropsychological tests. We used the PDQ-
39 single index score to measure QoL, which is validated for PD
and is widely used [8]. The MDS guidelines state that normative
values should be age, education, gender, and culturally appro-
priate [4]. As demonstrated in the results section, there were no
signiﬁcant differences between controls and PD participants in
terms of age, gender, education and premorbid intelligence
(NART score). Furthermore, control participants were not spouses
or relatives of PD participants to limit potential bias, and were
recruited locally through word of mouth and advertising to
reﬂect the community and cultural population. We also exam-
ined the scores and cut-offs for cognitive tests using age and
education as covariates. However, remodeling our data did not
have a signiﬁcant impact either on PD-MCI classiﬁcation or on
QoL.There are several limitations. The challenging nature of
accurately assessing MCI raises the possibility of falsely identi-
fying some participants as having MCI [4]. However, the use of
Level II criteria and the 2 SD as a cut-off for PD-MCI, in addition
to semi-structured interviews with participants and/or their
carers, increases diagnostic certainly. We used modiﬁed MDS
criteria since the study design predated the recent PD-MCI
guidelines. While the assessments for executive function, atten-
tion and memory were suitably covered, we had limited assess-
ments for language and particularly visuospatial function, which
included only one domain-speciﬁc test, which has implications
for classiﬁcation. However, language has been shown to be
relatively preserved in previous studies [9,30] and impaired
ability to copy pentagons has been shown to predict dementia
[5]. Furthermore, MoCA scores in patients with PD-MCI at 2 SD
(mean score of 22.3) were low in our study and below the cut-off
that suggests possible dementia. This mean is nonetheless
comparable with MoCA scores for PD-MCI from previous studies
[8], and ultimately dementia is not determined by MoCA score
alone and all participants underwent rigorous clinical assess-
ment to exclude dementia (including a caregiver interview).
Participants were recruited from outpatient clinics and 84% were
on antiparkinsonian medication, which reﬂects current clinical
practice.
This cohort will be followed longitudinally as part of a larger
incidence study to track the relationship between changes in
cognition and variations in QoL. This will establish an accurate
diagnosis and ascertain how QoL is affected by declining cogni-
tion from PD-MCI to PDD [4]. We have found that cognitive
impairment speciﬁcally contributes, independently, to poorer
QoL even in early PD. More marked degrees of PD-MCI (2 SD
below normal values) have a greater impact upon QoL, suggest-
ing a transition effect.
Increased awareness and understanding of the impact of PD-
MCI would inform clinicians of which cognition focused in-
terventions, such as cognitive training or cognitive stimulation in-
terventions, are potentially beneﬁcial [9]. Targeting speciﬁc
cognitive impairments to improve everyday function, ADL and
coping strategies may also have a direct positive impact on QoL
[26,27]. Increased understanding would also inform clinicians on
disease modifying medication; dopaminergic medication, for
example, may have an ameliorating effect on executive function,
impacting on QoL [10]. Consequently, studies investigating cogni-
tive or disease modifying interventions should include QoL
measures.Conﬂicts of interest
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